3 Reasons to Buy Eli Lilly Stock

Eli Lilly reported blockbuster quarterly results with Q4 sales of $19.3 billion, up 43% year‑over‑year, and adjusted EPS of $7.54, up 42% YoY; management guided 2026 revenue to $80–$83 billion (roughly 25% growth at midpoint). The company’s tirzepatide franchises (Mounjaro/Zepbound) generated well over $30 billion in 2025 and Lilly claimed a 60.5% share of the incretin analog market versus Novo Nordisk’s 39.1%, while pipeline assets — including oral GLP‑1 orforglipron (potential approval by Q2 2026) and phase‑3 retatrutide — promise further upside to its diabetes/weight‑management leadership. These results and guidance materially reinforce Lilly’s fundamentals and competitive position, supporting a positive investment thesis for the stock.

Analysis

Market structure: Lilly (LLY) is shifting pricing power and prescribing dynamics in GLP-1/incretin markets — tirzepatide >$30bn sales (2025) and 60.5% incretin share vs Novo Nordisk (NVO) 39.1% compress incumbent economics for NVO and retail/wholesale margins. Expect continued demand concentration in large-cap pharma names and healthcare ETFs; smaller weight-loss/diabetes suppliers lose bargaining power and may face consolidation or margin erosion within 12–24 months.

Risk assessment: Key tail risks are regulatory (U.S. price controls or Medicare negotiation expanding beyond current requests), class-action safety suits, or a failed FDA decision for orforglipron (approval window Q2 2026) that could erase 20–40% of forward momentum; manufacturing disruption or insurer formulary exclusions could shave 10–30% off near-term revenue. Time buckets: immediate (days) reaction to approval headlines; short-term (weeks–months) repricing around FDA and earnings; long-term (years) depends on pipeline commercialization and pricing environment.

Trade implications: Favor directional LLY exposure tied to upcoming catalysts — buy-dated options/LEAPs around Q2 2026 approval outcomes and use pair trades (long LLY / short NVO) to isolate GLP-1 share shifts; use covered-call overlays or short-dated hedges to monetize elevated implied volatility if buying stock. Cross-asset: stronger LLY narrative can tighten credit spreads for large pharma, marginally lift USD on risk-on flows, and damp safe-haven Treasuries if equity flows accelerate.

Contrarian angles: Consensus underestimates regulatory tightening probability and insurer backlash — upside may be priced for perfection; conversely, market may underprice LLY’s pipeline optionality (retatrutide, oral GLP-1) which could extend dominance beyond 2027. Historical parallel: rapid market-share swings in insulin pricing/competition show both fast adoption and sudden reimbursement pushback; plan for mean reversion windows of 20–30% in stock moves.

Key Decisions for Investors

• Establish a 2–3% long position in LLY (equal-weighted for portfolio) within 1–4 weeks, targeting a 12–18 month hold; set a take-profit at +25% and a hard stop-loss at -15% or hedge with 6–9 month puts if downside volatility rises.
• Execute a relative-value pair trade: go long LLY and short NVO in equal dollar notional (1:1) sized at 1–2% of portfolio to capture further GLP-1 share shifts; tighten stops at 12% adverse move and reassess after the Q2 2026 orforglipron FDA window.
• Buy 12–24 month LLY LEAP calls (e.g., Jan 2028 expiries) sized at 1% notional as asymmetric upside exposure to pipeline (retatrutide, orforglipron); finance by selling 3–6 month OTM covered calls (income) to lower carry if holding stock.
• If uncomfortable owning equity, implement a directional call spread ahead of Q2 2026 (buy 6–9 month ATM call / sell OTM call 10–20% higher) to capture approval upside while limiting premium outlay; cap max loss at the premium paid.
• Reduce small-cap biotech exposure by 2–4% and rotate into large-cap pharma/healthcare ETFs (XLV, VHT) over 4–8 weeks to benefit from sector consolidation; monitor for regulatory headlines (Medicare pricing, FDA briefs) in next 30–90 days as stop/trade triggers.